Melanotan II is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of Melanotan II is not precisely established; effects persist longer than MT-I. This means dosing every other day is typical to maintain stable levels. The half-life directly affects how long Melanotan II remains active and influences optimal injection timing.
What Is the Half-Life of Melanotan II?
The half-life of Melanotan II is not precisely established; effects persist longer than MT-I. This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer Melanotan II to maintain therapeutic blood levels.
What Does Melanotan II's Half-Life Mean for Dosing?
With a half-life of not precisely established; effects persist longer than MT-I, Melanotan II requires dosing every other day to maintain stable levels. The standard dosage of 250-500 mcg per injection via subcutaneous injection accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, Melanotan II reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For Melanotan II, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject Melanotan II?
Optimal timing depends on your research goals. A half-life of not precisely established; effects persist longer than MT-I means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (every other day) for more stable levels throughout the day.
How Does Melanotan II's Half-Life Compare to Similar Peptides?
Melanotan II is a Non-selective melanocortin receptor agonist. Its half-life of not precisely established; effects persist longer than MT-I positions it with a longer duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your Melanotan II Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Melanotan II.
Open Calculator →Bottom Line: Melanotan II Half-Life and Dosing
Melanotan II has a half-life of not precisely established; effects persist longer than MT-I, supporting the standard protocol of 250-500 mcg per injection dosed every other day over 2-4 weeks for tanning effects.
Read our Melanotan II dosage guide for complete protocol details.
Complete Guide
Melanotan II: Research
Related Reading
- Melanotan II Dosage Guide
- Melanotan II Benefits
- Melanotan II Side Effects
- Melanotan II Stacking Guide
- Melanotan II Cycle Guide
- Melanotan II Research
Research-Grade Sourcing
If you're going to research Melanotan II, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Melanotan II?
Melanotan II (Melanotan II (cyclic α-MSH analog)) is a Non-selective melanocortin receptor agonist. Synthetic cyclic α-MSH analog with non-selective activity across MC1, MC3, MC4, and MC5 receptors. It is researched for rapid skin darkening, appetite suppression, erectile function enhancement, increased libido.
What is the recommended Melanotan II dosage?
Common dosages: 250-500 mcg per injection administered every other day via subcutaneous injection. Cycle length: 2-4 weeks for tanning effects. Half-life: not precisely established; effects persist longer than MT-I. Use our peptide calculator for exact reconstitution math.
What are the side effects of Melanotan II?
Extensive adverse effects: nausea, vomiting, facial flushing, involuntary erections, yawning, loss of appetite. Serious reports of rhabdomyolysis, renal infarction, posterior reversible encephalopathy syndrome, and sympathomimetic toxicity. Increased melanoma risk, atypical moles, melanonychia (nail darkening). Dose-dependent toxicity.
Is Melanotan II safe?
Melanotan II has shown a preliminary safety profile in research. Not FDA-approved. Banned for human use in many jurisdictions. Warnings issued by US FDA, UK MHRA, and other health agencies. WADA banned. All research should follow appropriate safety protocols.